MYGN stock forecast
Our latest prediction for Myriad Genetics, Inc.'s stock price was made on the Nov. 6, 2023 when the stock price was at 16.34$.
In the short term (2weeks), MYGN's stock price should underperform the market by -1.65%. During that period the price should oscillate between -8.25% and +3.60%.
In the medium term (3months), MYGN's stock price should underperform the market by -0.61%. During that period the price should oscillate between -22.05% and +10.28%.
Get email alertsCreate a solid portfolio with MYGN
About Myriad Genetics, Inc.
myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.
At the moment the company generates 190M USD in revenues.
On its last earning announcement, the company reported a loss of -3.04$ per share.
The book value per share is 13.61$
Three months stock forecastNov. 6, 2023
Financials
| Revenue USD | Gross Margin | Operating Income | Operating Margin | Net Income | Earnings Per Share | Dividends | Payout Ratio | Shares | Book Value Per Share | Operating Cash Flow | Cap Spending | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 190M | 211.19% | -210M | -110.88% | -193M | -3.04 | - | - | 81M | 13.61 | - | - | - |